Compassionate use of psychedelics

Area of Science:

• Psychiatry
• Medical Ethics
• Neuroscience

Background:

• Psychedelic substances like psilocybin and MDMA show promise in therapeutic settings.
• Public controversy surrounding psychedelics necessitates ethical evaluation for their use in psychotherapy.
• Compassionate use of psychedelic-assisted therapies requires robust ethical justification.

Purpose of the Study:

• To ethically justify compassionate psychedelic psychotherapy.
• To assess the moral permissibility and rationality of psilocybin- and MDMA-assisted therapies.
• To address objections concerning potential epistemic harm from psychedelic psychotherapy.

Main Methods:

• Review of safety and efficacy data for psilocybin and MDMA in therapeutic contexts.
• Ethical analysis of compassionate use models for psychedelic therapies.
• Evaluation of arguments regarding epistemic harm in psychedelic-assisted psychotherapy.

Main Results:

• Psilocybin and MDMA-assisted therapies demonstrate promising results when combined with psychotherapy.
• It can be rational for certain patients to consider psychedelic therapy, even with uncertain outcomes.
• The expected value of psychedelic psychotherapy may exceed that of conventional or palliative care.
• Current evidence does not substantiate claims that psychedelic psychotherapy is epistemically harmful.

Conclusions:

• Compassionate psychedelic psychotherapy, particularly with psilocybin and MDMA, is argued to be morally permissible.
• The rationality of pursuing psychedelic therapy is supported by its potential benefits outweighing risks for some patients.
• Ethical frameworks can accommodate the use of psychedelic-assisted therapies, addressing concerns about safety, efficacy, and potential harms.